PubMed1 Apr 2026Clinical obesity● 6/10i GLP-1 Receptor Agonists Versus Bariatric Surgery: Effects of Weight Loss and BMI on Subsequent General Surgical Procedures.
Zindani S, Woldesenbet S, Altaf A, Khalil M, Rashid Z et al.
Bariatric surgery reduces BMI by 9.89 points more than GLP-1 receptor agonists before general surgery procedures, with 13% lower complication odds versus GLP-1RAs. Retrospective cohort study of 9,470 patients from Epic Cosmos database, 2016-2024, with entropy balancing for baseline differences. This provides the first head-to-head comparison of weight loss interventions on surgical outcomes, challenging the assumption that GLP-1RAs offer equivalent perioperative risk reduction. Study lacks a no-intervention control group, limiting conclusions about absolute benefit of either approach.
Strategic Signal
This real-world evidence creates a medical narrative problem for GLP-1RA manufacturers facing bariatric surgery comparisons in perioperative care protocols. Hospital systems and surgical societies will use this data to justify bariatric surgery referrals over medical management for high-risk surgical candidates. Novo Nordisk and Eli Lilly need head-to-head perioperative outcome studies to counter this positioning, particularly as value-based care contracts increasingly include surgical complication metrics.
GLP-1Weight lossReal-world evidence
Original Abstract
Obesity and T2DM substantially increase postoperative risk, with higher surgical site infections in obesity and up to a 65% increase in overall complications in T2DM. This study assesses the impact of weight loss interventions-metabolic bariatric surgery (MBS) and glucagon-like peptide-1 receptor agonists (GLP-1RA)-on BMI reduction and how that translates to postoperative outcomes in general surgery patients. Patients undergoing general surgery (2016-2024) were identified in the Epic Cosmos database. GLP-1RA or MBS exposure occurred 1-3 years preoperatively (GLP-1RA coverage ≥ 80%). Entropy balancing produced weighted cohorts with similar baseline profiles, followed by multivariable regression models assessing the association between weight loss intervention and BMI change, and the impact of BMI on postoperative outcomes. Overall 9470 individuals underwent a general surgery procedure. Median patient age was 64, with mostly females (60.6%). More patients received GLP-1RA (n = 7823, 82.3%) than MBS (n = 1647, 17.4%). MBS patients had higher initial BMIs (≥ 40: 60.8% vs. 24.5%, p < 0.001). MBS led to greater BMI reduction than GLP-1RA (Mean difference: -9.89, 95% CI: -9.64, -10.34). Higher BMI at time of a general surgical procedure correlated with increased postoperative complications (OR: 1.01, 95% CI: 1.00-1.01) and extended LOS (OR: 1.01, 95% CI: 1.00-1.01). MBS was associated with lower complication odds (OR: 0.87, 95% CI: 0.78-0.98). MBS improved surgical outcomes in patients with obesity and T2DM through greater BMI reduction compared with GLP-1RAs. These findings support the role of preoperative weight loss to mitigate surgical risk; however, evaluating outcomes relative to no intervention remains an important future direction.